Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated with Reference Ranibizumab for Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion
In this large real-world study, eyes with nAMD, RVO, and DME switched to ranibizumab-eqrn from reference ranibizumab demonstrated similar efficacy.
Authors
- Nikhil K. Bommakanti (ORCID: https://orcid.org/0000-0001-5429-0670)
- Yoshihiro Yonekawa (ORCID: https://orcid.org/0000-0002-6847-7169)
- Bita Momenaei (ORCID: https://orcid.org/0000-0002-5435-7369)
- Ajay E. Kuriyan (ORCID: https://orcid.org/0000-0002-2824-3245)
- Michael N. Cohen (ORCID: https://orcid.org/0000-0002-9125-0499)
- Carl D. Regillo (ORCID: https://orcid.org/0000-0001-8260-9925)
- Kristine Y. Wang (ORCID: https://orcid.org/0009-0009-7951-6838)
Institutions
- Wills Eye Hospital (US)
Publication Details
- Journal
- Current Eye Research
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1080/02713683.2025.2551165
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71